Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial
Osteoporosis International, 10/06/09
Eastell R et al. – Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.
Methods- Randomized, controlled trial of once-yearly ZOL
- 233 women
- lumbar spine, total hip, femoral neck, and trochanter assessed by DXA and QCT
- Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) evaluated
- Mean between-treatment differences for lumbar spine BMD were significant by DXA and QCT
- Between-treatment differences were significant for trabecular spine , trabecular trochanter ,total hip , and compressive strength indices at femoral neck , and trochanter
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of vertebral fractures is specific for gender and site of bone mineral density measurement
Journal of Rheumatology, 11/19/09
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis
Journal of Rheumatology, 11/19/09
Sponsor
Article Search
Sponsor